Suf­fer­ing a se­ries of set­backs, Eli Lil­ly's on­col­o­gy group qui­et­ly ex­e­cutes 2 of its top mid-stage drugs

Eli Lil­ly took a hit Tues­day morn­ing as the phar­ma gi­ant re­vealed just how painful its with­draw­al of Lartru­vo will be for its on­col­o­gy op­er­a­tions while the Cialis fran­chise gets eat­en up by gener­ics. Less vis­i­ble was a de­ci­sion to dump two mid-stage drugs from its pipeline op­er­a­tions, both of which had fig­ured promi­nent­ly as one of its best longterm hopes in the field.

Out in the Q1 cleanup at Lil­ly is the CHK1 drug prex­as­ert­ib (LY2606368) and their Phase II PI3k/mTOR in­hibitor, LY3023414. Both of these drugs were spot­light­ed in the sum­mer of 2017, as Eli Lil­ly an­nounced plans to con­cen­trate their R&D group in on­col­o­gy on 7 key pro­grams they felt had the best shot at go­ing on to be­com­ing ma­jor play­ers in the mar­ket. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.